Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease
- PMID: 18597574
- PMCID: PMC10437323
- DOI: 10.18553/jmcp.2008.14.5.451
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease
Abstract
Background: Sustained treatment with a cholinesterase inhibitor (ChEI) is used in the management of the symptoms of Alzheimer's disease (AD). However, the characteristic declines in learning and memory seen in AD may erode the patient's ability to adhere to medication regimens with or without caregiver support.
Objectives: To examine differences by type of ChEI in (1) monthly prevalence of use, (2) nonpersistence, (3) switching from the index drug to another ChEI, (4) number of days on therapy, (5) medication possession ratio (MPR), and (6) an estimate of the relationship of these characteristics to total annual health care expenditures.
Methods: Data were from the MarketScan Medicare Supplemental and Coordination of Benefits 2001-2003 database, which comprised 1.47 million Medicare beneficiaries during this 3-year time period. Inclusion criteria were: (1) aged 65 years or older; (2) at least 1 claim with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 331.0 for AD in any of 15 diagnosis fields on outpatient claims or any of 2 diagnosis fields on inpatient claims at any time during 18 months of observation; (3) at least 1 pharmacy claim for donepezil, galantamine, or rivastigmine preceded by a 6-month period without a ChEI claim; and (4) at least 12 months of follow-up data, for a minimum 18 months continuous enrollment. Multivariate analyses, including logistic regression and exponential conditional mean models, tested for cohort differences in ChEI utilization, controlling for demographics, region of the country, type of insurer, and the Charlson Comorbidity Index (comorbid diagnoses). Using exponential conditional mean models, we also examined the relationship between utilization characteristics and all-cause (i.e., not specific to AD) health care expenditures for a 12-month period, including inpatient and outpatient (physician) care, laboratory and radiology services, emergency room (ER) use, prescription drugs, and long-term care services (e.g., nursing home care, home health visits) paid by Medicare or private insurance, but excluding long-term care services paid by Medicaid. Expenditure was defined as allowed charge (i.e., the total payment received by the service provider including plan and patient paid amounts.)
Results: More than 70% of the patients who received ChEI therapy and who otherwise met the inclusion criteria were excluded from this study due to the absence of at least 1 claim with a diagnosis for AD. Of the 3,177 patients included in the study, the index ChEI was donepezil for 62.8% of the patients (n=1,994); 17.2% received galantamine (n=546) and 20.1% received rivastigmine (n=637). The total number of days of index therapy dispensed was greater for those starting on donepezil (mean [median, SD] days=226 [263, 115]) compared with rivastigmine (206 [233, 120], P<0.001), but was not significantly different compared with galantamine (216 [250, 119], P=0.085). Monthly prevalence of use was similar for the 3 drugs until month 5 when a smaller proportion of rivastigmine patients had index medication on hand (65.9%) compared with 72.1% of donepezil patients (P=0.003) and 72.7% of galantamine patients (P=0.012). At 12 months, the likelihood of receiving the index ChEI was higher for donepezil (61.1%) than for either rivastigmine (50.1%, P<0.001) or galantamine (56.4%, P=0.048) and was higher for galantamine than for rivastigmine (P=0.030). The rate of switching for donepezil patients was significantly lower (14.5%) than the switch rate for rivastigmine patients (21.5%, P<0.001) and was similar to the switch rate for galantamine patients (15.0%, P=0.781 for donepezil vs. galantamine; P=0.004 for galantamine vs. rivastigmine). Rates of nonpersistence, measured as having at least 1 gap in therapy of 30 days or more during the 1-year follow-up, were 63.5% for donepezil, 63.7% for galantamine (P=0.933 for donepezil vs. galantamine), and 68.0% for rivastigmine (P=0.042 for donepezil vs. rivastigmine). MPRs and total days supply of any ChEI did not significantly differ among the 3 drugs. Results of multivariate models showed that, controlling for index ChEI drug, each additional month of ChEI treatment was associated with a reduction of 1% in total all-cause health care costs. The mean (SD) total all-cause 1-year health care costs for patients initiated on the 3 ChEIs were not significantly different: $12,112 ($16,437) for donepezil, $12,137 ($19,154) for galantamine (P=0.978), and $12,853 ($14,543) for rivastigmine (P=0.278).
Conclusions: During the first year following initiation of ChEI therapy, patients initiated on donepezil had a greater days supply of the index medication than did patients initiated on rivastigmine. At 12 months following treatment initiation, the proportion of patients in therapy was higher for donepezil than for either rivastigmine or galantamine and was higher for galantamine than for rivastigmine. Patients treated with either donepezil or galantamine were less likely to switch from the index drug to another ChEI than were patients treated with rivastigmine. All-cause 1-year health care costs for patients initiated on the 3 ChEIs were not significantly different.
Comment in
-
Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts.J Manag Care Pharm. 2008 Jun;14(5):462-4. doi: 10.18553/jmcp.2008.14.5.462. J Manag Care Pharm. 2008. PMID: 18597575 Free PMC article. No abstract available.
Similar articles
-
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Health Technol Assess. 2012. PMID: 22541366 Free PMC article. Review.
-
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.Am J Geriatr Pharmacother. 2006 Jun;4(2):154-60. doi: 10.1016/j.amjopharm.2006.06.002. Am J Geriatr Pharmacother. 2006. PMID: 16860262
-
Cholinesterase inhibitors for Alzheimer's disease.Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article. Review.
-
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.Am J Geriatr Pharmacother. 2005 Jun;3(2):92-102. doi: 10.1016/j.amjopharm.2005.07.001. Am J Geriatr Pharmacother. 2005. PMID: 16129386
-
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. doi: 10.1017/s026646230200034x. Int J Technol Assess Health Care. 2002. PMID: 12391943 Review.
Cited by
-
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.Alzheimers Res Ther. 2023 Aug 3;15(1):130. doi: 10.1186/s13195-023-01271-0. Alzheimers Res Ther. 2023. PMID: 37537656 Free PMC article.
-
Specialist Availability and Drug Adherence in Older Adults with Dementia Across Regions of the United States.J Alzheimers Dis. 2023;93(3):927-937. doi: 10.3233/JAD-220620. J Alzheimers Dis. 2023. PMID: 37125546 Free PMC article.
-
Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study.J Alzheimers Dis. 2022;90(3):1177-1186. doi: 10.3233/JAD-220200. J Alzheimers Dis. 2022. PMID: 36213993 Free PMC article.
-
The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment.Am J Geriatr Psychiatry. 2019 Aug;27(8):873-882. doi: 10.1016/j.jagp.2019.02.003. Epub 2019 Feb 7. Am J Geriatr Psychiatry. 2019. PMID: 30910421 Free PMC article.
-
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132. Brain. 2018. PMID: 29850777 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous